Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 20;30(1):113-116.
doi: 10.3760/cma.j.cn501113-20201224-00675.

[Drug selection for simultaneous treatment of tuberculosis combined with hepatitis C virus infection]

[Article in Chinese]
S W Ma  1 , J R Wang  1 , Y M Zhu  1
Affiliations

[Drug selection for simultaneous treatment of tuberculosis combined with hepatitis C virus infection]

[Article in Chinese]
S W Ma et al. Zhonghua Gan Zang Bing Za Zhi. .

Abstract
in English, Chinese

Clinically, patients with tuberculosis (TB) combined with hepatitis C virus (HCV) infection often require simultaneous treatment. Consequently, when anti-HCV and TB drugs are used in combination drug-drug interactions (DDIs), anti-TB drug-induced hepatotoxicity, and liver disease states need to be considered. This paper focuses on discussing the metabolic mechanisms of commonly used anti-TB and HCV drugs and the selection options of combined drugs, so as to provide rational drug use for TB patients combined with HCV infection.

临床上经常遇到结核病（TB）合并丙型肝炎病毒（HCV）感染者需要同时治疗。当抗HCV和抗TB药物联用时需要考虑药物-药物之间的相互作用（DDIs）、抗TB药物诱导的肝毒性，以及肝脏疾病状态。现重点讨论常用抗TB和抗HCV药物的代谢机制和联用药物的选择，为TB合并HCV感染患者提供合理的用药选择。.

Keywords: Antiviral treatment regimen; Drug metabolism; Drug-drug interactions; Drug-induced liver injury; Hepatitis C virus; Liver cirrhosis; Tuberculosis.

PubMed Disclaimer

Substances